Two out of four studies described the use of anti-ALK medications in an ALK mutated NSCLC cohort [46,48], while the remaining two studies concerned a cohort of patients included regardless of molecular characteristics of the tumor. This evidence concerns the gene ALK and non-small cell lung carcinoma.